Wang Jing-Jing, Yan Li
Department of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Department of Respiratory and Critical Care Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Transl Cancer Res. 2022 Dec;11(12):4434-4440. doi: 10.21037/tcr-22-2873.
The prognosis of patients with malignant pleural mesothelioma (MPM) is poor, and early diagnosis is key to improving the prognosis. Pleural biopsy is the gold reference for diagnosing MPM, but it is an invasive method that can cause operation-related complications such as bleeding and infection. Serum biomarkers, with the advantages of mini-invasiveness, short turnaround time and objectiveness, represent a promising diagnostic tool for MPM.
We searched the PubMed database to identify clinical studies published between 1990 to July 2022 that investigated the diagnostic accuracy of serum biomarkers for MPM. The major findings of the verified studies were summarized.
Currently, there are many available serum markers for MPM, including mesothelin, soluble mesothelin-related peptides, osteopontin, fibulin-3, high mobility group box 1, and microRNA. Systematic review and meta-analysis evidence indicates that the sensitivity and specificity of these serum markers are less than 0.90. In addition, a large portion of previous studies have limitations, especially the representativeness of the study cohort.
The diagnostic accuracy of currently available serum biomarkers is unsatisfactory, and further studies are needed to investigate novel serum biomarkers.
恶性胸膜间皮瘤（MPM）患者的预后较差，早期诊断是改善预后的关键。胸膜活检是诊断MPM的金标准，但它是一种侵入性方法，可能会导致诸如出血和感染等手术相关并发症。血清生物标志物具有微创、周转时间短和客观等优点，是一种很有前景的MPM诊断工具。
我们检索了PubMed数据库，以识别1990年至2022年7月期间发表的调查血清生物标志物对MPM诊断准确性的临床研究。总结了经证实研究的主要发现。
目前，有许多可用于MPM的血清标志物，包括间皮素、可溶性间皮素相关肽、骨桥蛋白、纤连蛋白-3、高迁移率族蛋白B1和微小RNA。系统评价和荟萃分析证据表明，这些血清标志物的敏感性和特异性均低于0.90。此外，以前的大部分研究都存在局限性，尤其是研究队列的代表性。
目前可用的血清生物标志物的诊断准确性并不理想，需要进一步研究以探索新的血清生物标志物。
